Mechanism — how BPC-157 and TB-500 differ
BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of human gastric juice protein. Its proposed mechanism centres on multi-axis tissue-repair signalling — angiogenic-axis modulation, growth-factor-axis interaction and broader repair-pathway activation.
TB-500 is a synthetic peptide based on the active region of thymosin beta-4 (Tβ4) — a 43-residue naturally occurring peptide whose primary documented function is actin sequestration. TB-500's proposed research mechanism centres on the same actin-binding axis, with downstream effects on cell migration, angiogenesis and tissue remodelling.
Receptor profile
BPC-157 does not act through a single canonical receptor — published research suggests interactions with multiple growth-factor and angiogenic pathways simultaneously.
TB-500 acts through the thymosin-β4 actin-binding axis rather than a conventional cell-surface receptor. The actin-binding mechanism is the proposed basis for its cell-migration and tissue-remodelling effects in research models.
Pharmacokinetics and half-life
BPC-157 is a 15-residue peptide with notable stability in gastric conditions — oral, subcutaneous and intraperitoneal research-administration routes are documented. Research cadences vary depending on the route.
TB-500 is a longer peptide fragment with a different stability profile from BPC-157. Research cadences in published preclinical work are typically less frequent than BPC-157 cadences, reflecting the different pharmacokinetic profile.
Research applications
BPC-157 is widely used in research models of tendon, ligament, muscle, gastrointestinal and skin tissue repair, and in angiogenesis research. The multi-axis profile gives it a wide research-application footprint.
TB-500 is widely used in research models of cell migration, wound healing, angiogenesis and tissue remodelling. The actin-binding axis makes it a common comparator against other regenerative research peptides in cell-migration studies.
Analytical specification on every Regena batch
Both BPC-157 and TB-500 ship from Regena only after independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.
Batch COAs for both compounds are published on the Regena lab reports page so a research-peptide buyer can audit the analytical detail before purchase. The /trust/how-to-read-a-coa reference walks through every field on a modern Regena COA.
Handling, reconstitution and stability
Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a 28-day in-use stability window under refrigeration for both compounds.
Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both BPC-157 and TB-500 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.
When researchers choose BPC-157 vs TB-500
Researchers choose BPC-157 when the protocol targets multi-axis tissue-repair signalling or when a broader pharmacological footprint is preferred. Researchers choose TB-500 when the protocol targets the actin-binding axis specifically — cell migration, wound-healing or tissue-remodelling research models. Comparator panels frequently include both compounds in matched arms.
For multi-compound comparator studies, the Regena consultations team will reserve matched-batch inventory of both BPC-157 and TB-500 against a project timeline so the experimental panel is sourced under a single analytical specification window.
Regulatory and research-use framing
Both BPC-157 and TB-500 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.
Comparison pages on the Regena site exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.
Frequently asked questions
What is the main difference between BPC-157 and TB-500?+
BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of human gastric juice protein.
Which has the longer half-life, BPC-157 or TB-500?+
BPC-157 is a 15-residue peptide with notable stability in gastric conditions — oral, subcutaneous and intraperitoneal research-administration routes are documented. Research cadences vary depending on the route.
Are BPC-157 and TB-500 the same compound class?+
Both sit in the tissue-repair research peptides category but with distinct receptor profiles and pharmacokinetics — see the receptor-profile section above for the side-by-side detail.
What HPLC purity does Regena release each compound against?+
≥99.0% HPLC main-peak purity for both BPC-157 and TB-500, with matching mass-spectrometry molecular weight and water content within the published specification for each compound.
Who independently verifies the batches?+
Janoshik Analytical is the default independent verifier for both compounds; orthogonal independent laboratories are used when batch chemistry calls for second-method confirmation.
Can I order matched batches for a comparator study?+
Yes — the Regena consultations team will reserve matched-batch inventory of both compounds against a project timeline so the experimental panel is sourced under a single analytical specification window.
Are these peptides approved for human use?+
No. Both are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption, and are not dispensed against a prescription.
Where can I see the current batch COAs for both compounds?+
On the /coa lab reports page, indexed by compound and batch number. New batches appear within 24 hours of independent release.
Recommended next — keep comparing
Hand-picked links our research customers most often open after this page.